[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-metastases":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100646462","social-structural-and-lifestyle-drivers-of-prostate-cancer-disparities-100646462",false,"NCT07690579","Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities","Inclusion Criteria:\n\n* Participants who have elected radical prostatectomy as prostate cancer treatment.\n* Participants who have agreed to participate in the Urology Biobank.\n\nExclusion Criteria:\n\n* Participant does not plan nor schedule a radical prostatectomy (RP) procedure.","MALE","18 Years",{"count":18,"type":19},350,"ESTIMATED","OBSERVATIONAL","Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.\n\nThe explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.\n\nThese and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.",[23,24,25],"Prostate Cancer","Prostate Cancer Recurrent","Prostate Metastases",[27],"Radical Prostatectomy","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-08","ACTUAL",{"date":34,"type":32},"2026-03-31",{"date":36,"type":19},"2028-03-31",{"name":38,"class":39},"University of California, San Francisco","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100489720","phase-2-consolidative-prostate-radiotherapy-in-metastatic-prostate-cancer-100489720","NCT05656794","Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer","Consolidative Prostate Radiotherapy in Patients With Metastatic Prostate Cancer","CONSORT-PC","Inclusion Criteria:\n\n* Histologically-proven prostate cancer\n* Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)\n* Planned to or receiving systemic treatment ADT +\u002F- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)\n* Planned for EBRT\n* ECOG 0 or 1\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Prior radiotherapy to pelvis\n* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician\n* Any condition where radiotherapy is contraindicated","100 Years",{"count":51,"type":19},40,"INTERVENTIONAL",[54],"PHASE2","This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.",[25],"2026-03-18",{"date":59,"type":32},"2026-03-23",{"date":61,"type":32},"2023-08-09",{"date":63,"type":19},"2031-08",{"name":65,"class":39},"University Health Network, Toronto"]